Total revenues grew 66% y-o-y to $109.1 million for the fourth quarter of 2024 and 50% y-o-y to $399.0 million for the full-year 2024; Full-year 2025 revenue guidance of $560 million to $590 million ...

Avalo Therapeutics, Inc. has announced significant updates and financial results for 2024, highlighting a pivotal year marked by the acquisition of AVTX-009, a monoclonal antibody aimed at treating ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Respiratory syncytial virus (RSV) vaccine: Moderna received ...